DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis.BMC infectious diseases · 2021
   Pooled it
2. Immunological research landscapes and emerging immune mechanisms in HIV/HBV co-infection: a bibliometric analysis (2014-2024).Frontiers in immunology · 2026
   Review
3. Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India.BMC infectious diseases · 2025
   Observational
4. Genotyping and treatment issues with 'unusual' HCV 1 subtypes.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
   Article
5. 'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.Gut · 2024
   Review
6. Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data.Health science reports · 2023
   Article
7. Hepatitis C subtyping assay failure in UK patients born in sub-Saharan Africa: Implications for global treatment and elimination.Journal of medical virology · 2023
   Article
8. Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study.Open forum infectious diseases · 2022
   Article
9. Hepatitis C virus: A critical approach to who really needs treatment.World journal of hepatology · 2022
   Review
10. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions.World journal of hepatology · 2021
    Review
11. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.Viruses · 2021
    Article
12. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?Viruses · 2021
    Review
13. HCV Diagnosis and Sequencing Using Dried Blood Spots from Patients in Kinshasa (DRC): A Tool to Achieve WHO 2030 Targets.Diagnostics (Basel, Switzerland) · 2021
    Article
14. Amino Acid Substitutions Associated with Treatment Failure for Hepatitis C Virus Infection.Journal of clinical microbiology · 2020
    Article

Corrections and comments

• Comment on
  Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.2019

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as